Baxter has entered into a definitive agreement to acquire all of the hemophilia-related assets of Archemix, a privately-held biopharmaceutical company. The two companies have also entered into an exclusive license agreement for certain related assets. Archemix’s lead product ARC19499, is a synthetic, subcutaneously-administered hemophilia therapy currently in a Phase I trial. ARC19499 works by blocking Tissue Factor Pathway Inhibitor (TFPI) activity to increase and improve blood clotting, pot...